Отправить статью по E-mail Новые возможности патогенетической терапии миомы матки
- Авторы: Тихомиров А.Л.1
-
Учреждения:
- ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ
- Выпуск: Том 15, № 3 (2013)
- Страницы: 67-70
- Раздел: Статьи
- URL: https://journal-vniispk.ru/2079-5831/article/view/28242
- ID: 28242
Цитировать
Полный текст
Аннотация
В статье приведены результаты изучения эффективности применения селективного модулятора прогестероновых рецепторов – препарата Эсмия (улипристала ацетат) в лечении миомы матки.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Александр Леонидович Тихомиров
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ
Email: tikhomiroval@yandex.ru
д-р мед. наук, проф. каф. акушерства и гинекологии лечебного факультета ГБОУ ВПО МГМСУ
Список литературы
- Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лечения. Монография, М., 2013.
- Chabbert-Buffet N, Meduri G, Bouchard P et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005; 11: 293–307.
- Chwalisz K, Perez M.C, Demanno D et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26: 423–38.
- Donnez J, Tatarchuk T.F, Bouchard P et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. TV Engl J Med 2012; 366: 409–20.
- Donnez J, Tomaszewski J, Vazquez F et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. TV Engl J Med 2012; 366: 421–32.
- Mutter G.L, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21: 591–8.
- Home F.M, Blithe D.L. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007; 13: 567–80.
- Higham J.M, O'Brien P.M, Shaw R.W. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734–9.
- Janssen C.A, Scholten P.C, Heintz A.P. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977–82.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estrogen and Estrogen/Progestin Drug: Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms – Recommendations for Clinical Evaluation. Rockville, MD: Center for Drug Evaluation and Research (CDER) 2013. Available at: http://www.fda.gov/cder/guidance/index.htm
- Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic - pituitary - ovarian axis and endometrium in normal women: a prospective, randomized, placebo - controlled trial. J Clin Endocrinol Metab 2007; 92: 3582–9.
- Williams A.R.W, Bergeron C, Chabbert-Buffet N et al. Progesterone receptor modulator associated endometrial changes: a pilot histological dose escalation study of ulipristal acetate. Facts, Views and Vision in ObGyn. EBCOG. Sci J Flemish Soc Obstet Gynecol 2010; (abstr 163): 99.
- Kelly R.W, King A.E, Critchley H.O.D. Inflammatory mediators and endometrial function – focus on the perivascular cell. Reprod Immunol 2002; 57: 81–93.
- Baird D.T, Brown A, Critchley H.O.D et al. Effect of long - term treatment with low - dose mifepristone on the endometrium. Hum Reprod 2003; 18: 61–8.
- Williams A.R.W, Critchley H.O.D, Osei J et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007; 22: 1696–704.
- Hodgen G.D, van Uem J.F, Chillik C.F et al. Non - competitive anti - oestrogenic activity of progesterone antagonists in primate models. Hum Reprod 1994; 9 (Suppl. 1): 77–81.
- Chwalisz K, Brenner R.M, Fuhrmann U.U et al. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000; 65: 741–51.
- Brenner R.M, Slayden O.D, Nath A et al. Intrauterine administration of CDB-2914 (ulipristal) suppresses the endometrium of rhesus macaques. Contraception 2010; 81: 336–42.
- Croxatto H.B, Kovacs L, Massai R et al. Effects of long - term low - dose mifepristone on reproductive function in women. Hum Reprod 1998; 13: 793–8.
- Lakha F, Ho P.C, Van der Spuy Z.M et al. A novel estrogen - free oral contraceptive pill for women: multicentre, double - blind, randomized controlled trial of mifepristone and progestogen - only pill (levonorgestrel). Hum Reprod 2007; 22: 2428–36.
- Fiscella J, Bonfiglio T, Winters P et al. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol 2011; 42: 947–53.
- Heikinheimo O, Vani S, Carpen O et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod 2007; 22: 2515–22.
- Mutter G.L, Olga B, Loffe R et al. Proellex effects on the endometrium. Gynecol Endocrinol 2008; 24 (Suppl. 1): 75.
- Loffe O.B, Zaino R.J, Mutter G.L. Endometrial changes from short - term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009; 22: 450–9.
- Slayden O.D, Nayak N.R, Burton K.A et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. Clin Endocrinol Metab 2001; 86: 2668–79.
- Heikinheimo O, Hsiu J.G, Gordon K et al. Endometrial effects of RU486 in primates – antiproliferative action despite signs of estrogen action and increased cyclin-B expression. Steroid Biochem Mol Biol 1996; 59: 179–90.
- Eisinger S.H, Bonfiglio T, Fiscella K et al. Twelve - month safety and efficacy of low - dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005; 12: 227–33.
- Donnez J, Tatarchuk T.F, Bouchard P et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409–20.
- Donnez J, Tomaszewski J, Vazquez F et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421–32.
- Stovall T.G, Muneyyirci-Delale O, Summitt R.L. Jr, Scialli A.R. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Obstet Gynecol 1995; 86: 65–71.
- Mutter G.L, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21: 591–8.
- Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873–90 (Erratum, Stat Med 1999; 18: 1293J).
- Hollander M, Wolfe D.A. Nonparamet - ric statistical methods. New York: John Wiley, 1973; р. 75–82.
- Viswanathan M, Hartmann K, Mc Koy N et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007; 154: 1–122.
- Hoffman R, Benz E, Shattil S et al. Disorders of iron metabolism: iron deficiency and iron overload. Hematology: basic principles and practice. 5th ed. New York: Churchill Livingstone, 2008; р. 453–68.
- Spitz I.M, Grunberg S.M, Chabbert-Buffet N et al. Management of patients receiving long - term treatment with mifepristone. Fertil Steril 2005; 84: 1719–26.
Дополнительные файлы
